All News
Birth Control Use in Lupus
d
MedPage Today
Published guidelines on lupus management urge that female patients plan and prepare carefully for pregnancy, and use contraceptives when it's not intended -- but these recommendations are only rarely followed, a registry study suggested.
Read Article
ACR Backs FDA Rule Change on Interchangeable Biosimilars
d
ACR
The American College of Rheumatology submitted comments to the U.S. Food & Drug Administration supporting their recent proposal to update the approval process for biosimilars’ interchangeability status by repealing the requirement for switching studies while also encouraging the FDA to continue monitoring the downstream effects of this policy to ensure transparency for patients and prescribing providers.
Read Article
New $$$ drugs are NOT usually steroid sparing, but a single center 716 RA pt study compared JAKi (n 156) vs bDMARDs (560) starts; JAKi assoc w/ more rapid GC reduction in1st 6 mos & 60% higher odds of GC D/C (adj OR 1.63) (>50% vs 40% @12 mos) https://t.co/shiDytQeBU https://t.co/dCjyw21uLd
Dr. John Cush RheumNow ( View Tweet)
Among spondyloarthritis patients with clinical enthesitis, 68% had no ‘active enthesitis’ on ultrasound. Conversely, of those without signs of clinical enthesitis, 15% showed subclinical enthesitis on ultrasound
↓ https://t.co/aVEvOmcEHK
ACR_Journals ACR_Journals ( View Tweet)
The new Covid KP.2 booster vaccines are becoming available throughout the US. Besides high-risk (e.g. age 65+, immunocompromised, comorbidities), one of the most important reasons to get boosted, often overlooked, is to reduce #LongCovid risk by ~50%. Agree with Marks at FDA… https://t.co/SgX7JiPRzH https://t.co/i0W4xadxjW
Links:
Eric Topol EricTopol ( View Tweet)
Check out a NEW review on the dichotomy of #glucocorticosteroids treatment in #rheumaticdiseases by @maurizio_cutolo and team
👉https://t.co/6c08ucQlDN
👨🎓Glucocorticosteroids - a double-edged sword https://t.co/VdKlPzFpOb
Links:
@ReumatologiaJ ReumatologiaJ ( View Tweet)
Causes of Carpal Tunnel Syndr: obesity, repetitive wrist movements, pregnancy, RA, PsA. but also Sjögren's syndrome, Behcet's disease and systemic sclerosis (weaker) https://t.co/ssrs8UJEpX
Dr. John Cush RheumNow ( View Tweet)
RISE registry study shows Prednisone Rx before rheum consult ends up with more long-term Pred. 1,733 RA pts; 715 on GC (41% 0.5-2 mos before rheum care). mean GC use =157 d. GC before rheum care associated with longer GC use https://t.co/UpeK4hwIN0 https://t.co/F8cuoX0ACq
Links:
Dr. John Cush RheumNow ( View Tweet)
Studies on Psoriatic Arthritis Prevention
PsA is a sequelae to chronic skin psoriasis. Whether cutaneous psoriasis is the pre-clinical phase of what may become PsA is oft debated and has been inadequately researched.
https://t.co/5ESROnS6xk https://t.co/8Yte7JESZf
Dr. John Cush RheumNow ( View Tweet)
Sequential Belimumab and RTX in SLE
Could disease control in active SLE patients be improved by the sequential use of subcutaneous BEL and intravenous RTX? A double blind trial has shown that sequential BEL and RTX was not superior to BEL alone in SLE.
https://t.co/CO0ltRX9Eo https://t.co/zey2UE4BRu
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 919 RTX-treated GPA pts shows TMP-SMX prophylaxis (given to 31%) assoc w/ reduced serious infections (adj HR 0.5) and less outpatient infections (aHR 0.8). All 13 pneumocystis infx (PJP) occured in those not Rx w/ TMP-SMX. https://t.co/bO6oAHv7Lr https://t.co/fPntW75hnY
Dr. John Cush RheumNow ( View Tweet)
Cohort of 112 VEXAS pts: skin involvement common (83%), esp early w/ LCV (36%), neutrophilic (34%) or perivascular dermatitis (30%). p.Met41Leu variant w/ PMN (Sweets?) dermatitis (82%); p.Met41Val variant w/ vasculitic lesions (55%). 92% respond to pred https://t.co/2ACXCGRsi5 https://t.co/tYqA26AlaF
Dr. John Cush RheumNow ( View Tweet)
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome - genetic disease with estimated prevalence of 1 in 4269 in men >50 year: systemic inflammation, progressive bone marrow failure, and inflammatory cutaneous manifestations https://t.co/hSmE64xzcU https://t.co/gWh4rvaaS3
Dr. John Cush RheumNow ( View Tweet)
Gluten can be "a wicked antigen". Full read Review of the potential role of gluten in inflammation and autoimmunity. Undigested gluten peptides can be modified by luminal transglutaminase or delivered to gut mucosal immune cells https://t.co/eonHfpZZiN https://t.co/iKwbzg2Lbu
Dr. John Cush RheumNow ( View Tweet)
AR882, a URAT1 inhibitor, was given FDA Fast Track designation for potential treatment of clinically visible tophi in patients with gout. In the US 13 mill have gout & 2 mill have visible tophi. AR882 was presented at EULAR24 https://t.co/StvD3iz9AD https://t.co/G9SzxJysSD https://t.co/KcUSPVb5pn
Links:
Dr. John Cush RheumNow ( View Tweet)
2024 Update of EULAR recommendations for the Treatment of Systemic Sclerosis
https://t.co/52XEfgVCzZ https://t.co/d1zgTYUeOo
Dr. John Cush RheumNow ( View Tweet)
A Family History of Arthritis?
Using data from the population based All of Us Research Program, a self reported history of arthritis and related conditions was associated with an increased risk for arthritis, osteoporosis, and carpal tunnel syndrome.
https://t.co/SApbPLHquQ https://t.co/hOamnYyRoz
Dr. John Cush RheumNow ( View Tweet)
Lipids and Inflammation in Rheumatoid Arthritis
In the realm of chronic inflammation, lipid abnormalities are well-recognized as pivotal contributors to the progression and clinical manifestations of atherosclerosis. Particularly in rheumatoid arthritis (RA), a systemic… https://t.co/zHKbBHlap8 https://t.co/KRIg1KYmcC
Dr. John Cush RheumNow ( View Tweet)
Longitudinal US RA Registry of 31129 #RA pts (148K Pt-Yrs F/U) shows Higher RA Dz activity assoc w/ eGFR decline & renal dysfunction. Compared to remission, pts in Hi Dz activity had HR 1.27 risk for CKD G3a (<60cc) & HR 1.93 for CKD 3b (<45cc/min) https://t.co/UaFINRzqoM https://t.co/XXQviVO6jU
Dr. John Cush RheumNow ( View Tweet)
Tyk2 inhibitor/Zasocitinib (TAK-279) effective in Psoriasis. Ph II RDBPCT of 259 pts w/ mod- severe plaque PsO showed 12 week PASI 75 success in 68% & 67% on 15 - 30 mg zasocitinib qd vs Placebo (18%). https://t.co/yyZwBYAP3H https://t.co/TvSSlEAKtR
Dr. John Cush RheumNow ( View Tweet)